In the practice of market competition, we realize that competition mainly depends on innovation, especially technological innovation in key areas. To this end, in recent years, we have vigorously built Lianyungang, Shanghai Research Center and three major research centers in the United States. There are 300 researchers, including doctors, masters, returnees 150. The company's research center was rated as the national enterprise technology center and the "major new drug creation" incubation base, and the national postdoctoral research center was established. Over the past few years, the company has undertaken four major scientific and technological projects of the National 863 Program, seven major national projects of new drug creation, nine national torch programs, four national spark programs, 16 national key new product projects and dozens of provincial key scientific and technological projects, and applied for 69 invention patents, including 33 world patents. At present, two innovative drugs are undergoing phase III clinical trials and are expected to be listed in 2009. Strive to use 2-3 years of efforts, and 1-2 innovative drugs enter clinical research every year.
In order to take the initiative in the fierce market competition, we have established and improved the nationwide sales network system, and established three professional sales teams according to the classification of antineoplastic drugs, surgical drugs and OTC drugs. The company's annual sales of four products, including calcium folinate, exceed 1 billion yuan, and the annual sales of oxaliplatin and docetaxel exceed 400 million yuan. The company also actively expands the markets of the United States, Europe, India, South America and other countries and regions, and expands export channels. In 2008, the export volume of foreign trade exceeded 1 100 million yuan.
In the future, the company will continue to adhere to the innovative concept, take "creating a healthy life for the people" as the goal, devote itself to drug innovation, strive to open up the international market, and strive to build the company into a patented pharmaceutical enterprise in China.